Cara Therapeutics Company Profile (NASDAQ:CARA)

About Cara Therapeutics

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body's peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845, and CR701. The Company's I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. The Company is developing an oral version of CR845 for the treatment of moderate-to-severe acute and chronic pain. The Company's CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with cannabinoid receptor subtypes, with no off-target activities. CR701 is in preclinical-stage of development.

Industry, Sector and Symbol:

• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Exchange: NASDAQ
• Symbol: CARA
• CUSIP:

Key Metrics:

• Previous Close: $8.35
• 50 Day Moving Average: $6.36
• 200 Day Moving Average: $5.98
• 52-Week Range: $4.26 - $18.12
• Trailing P/E Ratio: N/A
• Foreward P/E Ratio: -4.94
• P/E Growth: 0.00
• Market Cap: $227.80M
• Outstanding Shares: 27,282,000
• Beta: 3

Profitability:

• Return on Equity: -38.43%
• Return on Assets: -36.03%

Debt:

• Current Ratio: 10.92%
• Quick Ratio: 10.92%

Additional Links:

• Visit Cara Therapeutics' Official Website
• View CARA on Google Finance
• View CARA on Yahoo Finance
• View CARA's Company Profile on Reuters
• Search for Cara Therapeutics Inc. on Google

Companies Related to Cara Therapeutics:

• Intersect ENT (NASDAQ:XENT)
• Arrowhead Research Corp. (NASDAQ:ARWR)
• OraSure Technologies (NASDAQ:OSUR)
• Sorrento Therapeutics (NASDAQ:SRNE)
• MyoKardia (NASDAQ:MYOK)
• La Jolla Pharmaceutical (NASDAQ:LJPC)
• Arena Pharmaceuticals (NASDAQ:ARNA)
• NewLink Genetics Corp. (NASDAQ:NLNK)
• XBiotech (NASDAQ:XBIT)
• Advaxis (NASDAQ:ADXS)

Earnings

Earnings History for Cara Therapeutics (NASDAQ:CARA)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call	Details
11/7/2016
8/4/2016	Q216	($0.42)	($0.48)	$0.13 million	$0.08 million	View	N/A
5/5/2016	Q116	($0.40)	($0.39)	$0.03 million	$0.01 million	View	N/A
3/10/2016	Q4	($0.33)	($0.35)	$0.53 million		View	Listen
11/9/2015	Q315	($0.27)	($0.19)	$1.86 million	$2.40 million	View	N/A
8/10/2015	Q215	($0.24)	($0.25)			View	Listen
5/12/2015	Q415	($0.27)	($0.21)	$0.70 million	$0.50 million	View	Listen
3/26/2015	Q4	($0.30)	($0.18)		$0.91 million	View	Listen
11/10/2014	Q314	($0.22)	($0.29)	$0.13 million	$1.13 million	View	N/A
8/7/2014	Q2	($0.27)	($0.16)	$0.08 million	$0.96 million	View	N/A
5/12/2014	Q1	($0.14)	($0.22)	$0.30 million	$0.18 million	View	N/A
3/27/2014		($0.18)	($0.49)			View	N/A

(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cara Therapeutics (NASDAQ:CARA)

Dividends

Dividend History for Cara Therapeutics (NASDAQ:CARA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cara Therapeutics (NASDAQ:CARA)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Details
4/20/2016	Frederique Ph.D. Menzaghi	VP	Sell	6,000	$9.00	$54,000.00
3/17/2016	Ventures Vi Lp Rho	Major Shareholder	Buy	400,000	$4.87	$1,948,000.00
2/3/2016	Frederique Ph.D. Menzaghi	VP	Sell	6,000	$9.04	$54,240.00
1/26/2016	Michael E Lewis	Insider	Sell	7,262	$10.93	$79,373.66
1/6/2016	Derek T Chalmers	CEO	Sell	12,500	$17.22	$215,250.00
12/1/2015	Frederique Ph.D. Menzaghi	VP	Sell	6,000	$16.21	$97,260.00
11/2/2015	Frederique Ph.D. Menzaghi	VP	Sell	6,000	$14.26	$85,560.00
10/1/2015	Frederique Ph.D. Menzaghi	VP	Sell	6,000	$13.95	$83,700.00
9/1/2015	Frederique Ph.D. Menzaghi	VP	Sell	7,000	$18.63	$130,410.00
8/18/2015	Josef Schoell	CFO	Buy	3,000	$22.10	$66,300.00
6/1/2015	Michael E Lewis	Insider	Sell	7,262	$9.50	$68,989.00
5/19/2015	Dean Slagel	Director	Sell	188,811	$10.02	$1,891,886.22
4/1/2015	Michael E Lewis	Insider	Sell	7,262	$9.90	$71,893.80
3/2/2015	Michael E Lewis	Insider	Sell	7,262	$10.11	$73,418.82
2/2/2015	Michael E Lewis	Insider	Sell	7,262	$10.60	$76,977.20
2/5/2014	Ventures Vi Lp Rho	Major Shareholder	Buy	225,818	$11.00	$2,483,998.00

(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cara Therapeutics (NASDAQ:CARA)

Date	Headline
	Pruritus Global Pipeline Review Research H2 2016 (NASDAQ:CARA) www.khq.com - September 30 at 8:31 AM
	Biotech Stocks To Put On Your Watch List: Cara Therapeutics Inc ... - The Voice Registrar (NASDAQ:CARA) voiceregistrar.com - September 29 at 3:36 PM
	Active biotech company shares in the news: Cara Therapeutics Inc ... - The Voice Registrar (NASDAQ:CARA) voiceregistrar.com - September 29 at 3:36 PM
	Overbuying Stock in the Spotlight: Cara Therapeutics Inc (NASDAQ:CARA) - Post Registrar (NASDAQ:CARA) postregistrar.com - September 29 at 3:36 PM
	Cara Therapeutics to Host Industry Symposium at the Orthopaedic ... - GlobeNewswire (press release) (NASDAQ:CARA) globenewswire.com - September 29 at 3:36 PM
	Cara Therapeutics to Host Industry Symposium at the Orthopaedic Trauma Association 2016 Annual Meeting (NASDAQ:CARA) finance.yahoo.com - September 29 at 8:57 AM
	Latest report on diabetic gastroparesis pipeline market analysis H2 2016 made available by top research firm (NASDAQ:CARA) www.whatech.com - September 28 at 3:56 PM
	Array Biopharma Inc (NASDAQ:ARRY), Cara Therapeutics Inc (NASDAQ:CARA) Gave Huge profit To Members At Traders Insights (NASDAQ:CARA) www.marketnewscall.com - September 28 at 3:56 PM
	Cara Therapeutics Inc (NASDAQ:CARA) Continues Volume-backed Uptrend - Scibility Media (NASDAQ:CARA) scibilitymedia.com - September 28 at 8:50 AM
	Pay Close Attention To These Analyst Ratings Atwood Oceanics, Inc ... - The Voice Registrar (NASDAQ:CARA) voiceregistrar.com - September 27 at 4:01 PM
	Time To Put On The Watch List? - Cara Therapeutics Inc. (NASDAQ:CARA), Conatus Pharmaceuticals Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:CARA) voiceregistrar.com - September 27 at 4:01 PM
	ETF’s with exposure to CARA Therapeutics, Inc. : September 27, 2016 (NASDAQ:CARA) www.capitalcube.com - September 27 at 4:01 PM
	Hot Biotech Stocks Recap: Cara Therapeutics Inc. (NASDAQ:CARA), Illumina Inc. (NASDAQ:ILMN) - The Voice Registrar (NASDAQ:CARA) voiceregistrar.com - September 23 at 3:30 PM
	EnterisBioPharma's Congratulates Cara Therapeutics Inc (NASDAQ:CARA) On Successful Phase II Clinical Trial - Scibility Media (NASDAQ:CARA) scibilitymedia.com - September 23 at 3:30 PM
	Pruritus Therapeutics Market: Segments, Opportunity, Growth and Forecast By End-use Industry 2015-2020 (NASDAQ:CARA) qwtjlive.com - September 22 at 4:14 PM
	Active News in Retreated Reviews- Mast Therapeutics, Inc. (NYSE ... - Seneca Globe (NASDAQ:CARA) www.senecaglobe.com - September 21 at 8:04 AM
	Xerox Corp (NYSE:XRX) & Cara Therapeutics Inc (NASDAQ:CARA) UPDATE ON U.S STOCKS: 19 SEP 2016 - Money News (NASDAQ:CARA) www.newsismoney.com - September 21 at 8:04 AM
	Enteris BioPharma's Feasibility to Licensing Partner, Cara Therapeutics, Advances ... (NASDAQ:CARA) www.biomedreports.com - September 20 at 9:55 AM
	Enteris BioPharma's "Feasibility to Licensing" Partner, Cara Therapeutics, Advances Peptelligence™-Engineered … (NASDAQ:CARA) finance.yahoo.com - September 20 at 9:55 AM
	Intraday Movers: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ... - NYSE Journal (press release) (NASDAQ:CARA) stockznews.com - September 19 at 4:53 PM
	Enteris BioPharma's "Feasibility to Licensing" Partner, Cara Therapeutics, Advances Peptelligence™-Engineered CR845 into Phase 2b Clinical Trial in Chronic Pain (NASDAQ:CARA) finance.yahoo.com - September 19 at 4:53 PM
	Cara Therapeutics : Initiates Enrollment in Phase 2b Trial of Peripherally Acting Kappa Opioid Agonist, Oral CR845, in Chronic Pain Patients (NASDAQ:CARA) www.4-traders.com - September 17 at 3:59 PM
	Cara Therapeutics Inc (NASDAQ:CARA): What We’re Looking For From The OA Trial (NASDAQ:CARA) streetregister.com - September 17 at 3:59 PM
	Cara Therapeutics Inc (NASDAQ:CARA): What We're Looking For ... - Street Register (NASDAQ:CARA) streetregister.com - September 17 at 8:51 AM
	Choyce Peterson negotiates 24,000 s/f lease for Cara Therapeutics (NASDAQ:CARA) cre.nerej.com - September 16 at 7:01 AM
	Cara Therapeutics (CARA) Commences CR845 Phase 2b Enrollment - StreetInsider.com (NASDAQ:CARA) www.streetinsider.com - September 15 at 12:35 PM
	Cara Therapeutics Initiates Enrollment in Phase 2b Trial of Peripherally Acting Kappa Opioid Agonist, Oral CR845, in Chronic Pain Patients (NASDAQ:CARA) www.publicnow.com - September 15 at 12:35 PM
	Cara Therapeutics: Major Upside Potential - Seeking Alpha (NASDAQ:CARA) seekingalpha.com - September 14 at 4:04 PM
	Shares in Focus: Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings & Targets Update - Frisco Fastball (NASDAQ:CARA) friscofastball.com - September 9 at 3:59 PM
	2 Sizzling Hot Biotechnology Stocks: Cara Therapeutics Inc. (CARA ... - National Daily Press (NASDAQ:CARA) www.nationaldailypress.com - September 9 at 3:59 PM
	2 Biotech Stocks News And Price Trends: Cara Therapeutics Inc. (NASDAQ:CARA), Agios Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:CARA) voiceregistrar.com - September 9 at 3:59 PM
	ETF’s with exposure to CARA Therapeutics, Inc. : September 9, 2016 (NASDAQ:CARA) www.capitalcube.com - September 9 at 3:59 PM
	Placing Cara Therapeutics, Inc. (NASDAQ:CARA) Shares Under the ... - Post News (NASDAQ:CARA) www.kentuckypostnews.com - September 8 at 6:34 AM
	My Watchlist for Thursday, September 08 (NASDAQ:CARA) ac-investor.blogspot.com - September 7 at 9:08 PM
	Pain management market – new discoveries and treatment options in abuse deterrent era published by leading research firm (NASDAQ:CARA) www.whatech.com - September 7 at 9:44 AM
	Pruritus Therapeutics Market: Size, Share, Dynamics and Trends by 2014 – 2020 (NASDAQ:CARA) www.medgadget.com - September 6 at 3:58 PM
	Here's Why Investors Should Steer Clear of Opioids (NASDAQ:CARA) www.thestreet.com - September 6 at 3:58 PM
	$CARA to Webcast Presentation (NASDAQ:CARA) marijuanastocks.com - September 4 at 8:43 AM
	Cara Therapeutics to Sponsor Symposium and Present Posters at ... - Nasdaq (NASDAQ:CARA) www.nasdaq.com - September 3 at 8:44 AM
	Cara Therapeutics to Webcast Presentation at 23rd Annual NewsMakers in the Biotech Industry Conference - EconoTimes (NASDAQ:CARA) www.econotimes.com - September 2 at 8:51 AM
	Cara Therapeutics to Webcast Presentation at 23rd Annual NewsMakers in the Biotech Industry Conference (NASDAQ:CARA) www.publicnow.com - September 2 at 8:51 AM
	$CARA to Sponsor Symposium and Present Posters at PAINWeek (NASDAQ:CARA) marijuanastocks.com - September 1 at 4:01 PM
	Cara Therapeutics Inc (NASDAQ:CARA) Is A Cheap Buyout Target - Street Register (NASDAQ:CARA) streetregister.com - September 1 at 12:32 PM
	MGT Capital Investments Inc. (NYSEMKT:MGT) Is About To Get Shareholder Approval To Shift up A Gear (NASDAQ:CARA) streetregister.com - August 31 at 8:52 AM
	Cara Therapeutics Inc (NASDAQ:CARA) Is A Cheap Buyout Target (NASDAQ:CARA) streetregister.com - August 30 at 11:55 AM
	Can Shares Of Cara Therapeutics, Inc. (NASDAQ:CARA) Get To $24? - Investor Newswire (NASDAQ:CARA) www.investornewswire.com - August 29 at 8:34 PM
	ETF’s with exposure to CARA Therapeutics, Inc. : August 29, 2016 (NASDAQ:CARA) www.capitalcube.com - August 29 at 3:27 PM
	Diversity of the Legal and Medical Marijuana Markets (NASDAQ:CARA) www.prnewswire.com - August 24 at 12:18 PM
	Zynerba Pharmaceuticals : Diversity of the Legal and Medical Marijuana Markets (NASDAQ:CARA) www.4-traders.com - August 24 at 12:18 PM
	Newly released market study: Cara Therapeutics, Inc. (CARA) - Financial and Strategic SWOT Analysis Review (NASDAQ:CARA) www.live-pr.com - August 24 at 12:18 PM

Social

Cara Therapeutics (NASDAQ:CARA) Chart for Saturday, October, 1, 2016